What is it about?
We found B7-H1 (PD-L1) has a new associated protein inside T cells. Disruption of B7-H1's function by certain antibody may impair T cell's anti-tumor function.
Featured Image
Why is it important?
Our study is important because we provide a new method to distinguish optimal and suboptimal anti-PD-L1 antibody for cancer immunotherapy.
Perspectives
Although immunotherapy based on targeting PD-1/PD-L1 pathway has demonstrated significant impact in cancer treatment, the efficacy is still low. Our current study will help to select an optimal anti-PD-L1 antibody for cancer treatment. Doing so, we will be able to avoid self-canceling effects of some anti-PD-L1 antibodies.
Dr. Haidong Dong
Mayo Clinic College of Medicine
Read the Original
This page is a summary of: B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells, Scientific Reports, November 2016, Nature,
DOI: 10.1038/srep36722.
You can read the full text:
Contributors
The following have contributed to this page
